Skip to content
drillr.ai
Sign up

02566.HK

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.

HKSE · Healthcare · Biotechnology · CN

HKD 5.25
−0.66%
Ask drillr

  • Aug 20, 2026, 02:08 UTC

    Jiyuan Gene announced that its board resolved to continue its H-share buyback plan, repurchasing up to 100 million RMB of H-shares on the open market with its own funds before the buyback mandate expires.

    Source:

  • Aug 20, 2026, 01:08 UTC

    Jiuyuan Gene announced its interim results for the six months ended June 2026, with revenue of RMB 631 million, down 1.2% year-on-year, and net profit of RMB 91.269 million, up 1.2% year-on-year.

    Source: